The Waiting-Room Playbook: Five Questions That Put Non-Opioid Pain Options on the Table

Most appointments for chronic pain last under 20 minutes. In that window, a patient navigating years of low back pain or knee osteoarthritis is often offered a short menu: physical therapy, an NSAID, an opioid. The non-opioid pipeline — a category that has expanded dramatically over the past decade — rarely comes up, not because clinicians dismiss it, but because nobody asks.

Preparation changes that. Below are five questions grounded in the current evidence landscape, phrased so they can be asked in plain English during a routine visit.

1. "Am I a candidate for anything besides pills — and what's the evidence for it?"

This opens the door to non-pharmacologic first lines with genuine trial backing: structured exercise, cognitive behavioral therapy, and, for knee osteoarthritis, weight management programs covered by many US insurers. Medicare now reimburses several of these pathways. Framing the question around evidence rather than preference signals that you want the full menu, not the fastest option.

2. "What do you think of SNRIs for my kind of pain?"

Serotonin-norepinephrine reuptake inhibitors — duloxetine is the best-known example — carry FDA approval for chronic musculoskeletal pain and diabetic neuropathy. They are neither new nor experimental, yet surveys suggest many patients on opioids were never offered one. Asking directly invites a conversation about a medication class with years of safety data behind it.

3. "I've read about nerve-growth-factor drugs. Where does that science stand?"

NGF inhibitors such as tanezumab were once billed as a potential opioid replacement for osteoarthritis. The program was ultimately shelved over joint-safety concerns, and no NGF inhibitor has reached US patients. That history is itself useful: it shows why asking about a drug's regulatory status matters. A compound in Phase II is a hypothesis; a compound with an FDA decision is a fact. Clinicians generally respect patients who know the difference.

4. "Are there clinical trials near me that I'd qualify for?"

ClinicalTrials.gov allows anyone to search active studies by condition and ZIP code. Pain trials run at academic centers across the country — including gene-therapy studies for specific neuropathies and repurposing trials testing drugs like low-dose naltrexone for fibromyalgia. Two cautions worth raising with your doctor: enrollment should never replace standard care without a fallback plan, and any trial that charges patients to participate is a red flag.

5. "If we do consider an opioid, what's the exit plan?"

This question is not anti-opioid; it is pro-planning. The 2022 CDC clinical practice guideline emphasizes that opioids, when used, should have defined goals and reassessment points. Asking about the taper strategy upfront — and documenting it — protects patients who want the option to stop later. It also signals to a clinician that you view opioids as one stop on a longer route, not the destination.

Making the Questions Count

Bring a written list. Note which options have already been tried and for how long — insurers frequently require documented failure of first-line treatments before covering others. And if a clinician dismisses the pipeline entirely, a second opinion at a multidisciplinary pain clinic is a reasonable next step; most major US hospital systems now operate one.

The non-opioid field has been humbled before — the tanezumab story proved that promising science can stall. But the landscape still holds approved alternatives, active trials, and a regulatory system increasingly oriented toward opioid-sparing care. Patients who arrive with informed questions are far more likely to hear about them.